Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2025-04-02 Major Shareholding Noti…
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (Hyundai Bioscience) regarding a 'Correction Report' (정정신고) for a 'Stock Collateral Agreement' (주식 담보제공 계약). This type of filing is a standard regulatory disclosure regarding changes in share collateralization by a major shareholder, which falls under the category of general regulatory announcements and filings that do not fit into more specific categories like M&A or Earnings Releases.
2025-04-02 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, specifically regarding major shareholders (CnPharm Co., Ltd.) and their special relations, including changes in shareholding percentages and collateral agreements. This type of filing is classified as a Major Shareholding Notification (MRQ) in the provided schema.
2025-04-01 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in Korea. This type of filing is specifically used to report changes in share ownership by company directors or major shareholders, which corresponds to the 'Director's Dealing' (DIRS) category in the provided taxonomy.
2025-04-01 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (Hyundai Bioscience) regarding a 'Correction Report' (정정신고) for a 'Contract for Stock Collateral Provision Involving a Change in the Largest Shareholder' (최대주주 변경을 수반하는 주식 담보제공 계약 체결). This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for reporting changes in collateralized shares by major shareholders. Since it does not fit into specific categories like M&A, Earnings, or Dividends, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2025-04-01 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (Hyundai Bioscience) regarding a 'Change in Major Shareholder's Stock Collateral Agreement'. It details the pledging of shares by the major shareholder (C&Pharm) as collateral for loans. This type of disclosure is a standard regulatory requirement for listed companies to report changes in the capital structure or significant encumbrances on shares held by major shareholders. It does not fit into specific categories like Earnings Release, Annual Report, or M&A, and is best classified as a general regulatory filing.
2025-03-31 Korean
정기주주총회결과 (제25기)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과) for Hyundai Bio. It details the outcomes of agenda items such as financial statement approval, director appointments, and remuneration limits, as well as voting results. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements.
2025-03-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.